| Study Period | 2019 - 2032 |
| Market Size in 2024 | USD 22.4 Billion |
| Market Size in 2025 | USD 22.6 Billion |
| Market Size by 2032 | USD 26.1 Billion |
| Projected CAGR | 2.1% |
| Largest Region | North America |
| Fastest Growing Region | APAC |
| Market Structure | Consolidated |
Explore the market potential with our data-driven report
The lateral flow assays market size was USD 22.4 billion in 2024, and it will grow by 2.1% during 2025–2032, to reach USD 26.1 billion by 2032.
The substantial growth in the lateral flow assays industry is primarily driven by the escalating prevalence of infectious diseases globally, the rapidly aging population with increasing chronic health needs, and the expanding adoption of point-of-care testing across healthcare settings.
The market has witnessed unprecedented transformation following the COVID-19 pandemic, which demonstrated the critical importance of rapid, accessible diagnostic tools in managing public health emergencies. This broadening application scope encompasses cardiac marker testing, pregnancy and fertility monitoring, drug-of-abuse screening, and food safety testing, positioning lateral flow assays as versatile diagnostic tools across multiple healthcare verticals. The convergence of technological advancements, including smartphone-compatible readers, artificial intelligence-powered result interpretation, and multiplex detection capabilities, has fundamentally enhanced the accuracy, connectivity, and usability of these devices, making them increasingly attractive for both professional healthcare settings and home-based testing scenarios.
Furthermore, the rise in the launch of novel diagnostic solutions is driving the growth of the market. For instance, in August 2025, Anbio Biotechnology introduced a Chikungunya IgM/IgG rapid test capable of quickly detecting antibodies in the blood, plasma, or serum using the immunochromatographic lateral flow technology.
The kits & reagents category held the largest market share, of 65%, in 2024. This can be ascribed to the rising number of application areas of lateral flow kits and reagents for point-of-care testing, the growing prevalence of chronic disorders, and the surging use of lateral flow kits in residential care, owing to their easy, comfortable, and convenient benefits. This substantial market dominance stems from the fundamental consumable nature of these components as each diagnostic test requires fresh kits and reagents to ensure accuracy and prevent cross-contamination. The segment encompasses critical materials, including nitrocellulose membranes, conjugate pads, sample pads, buffer solutions, and detection antibodies, all of which are essential for test functionality.
The lateral flow readers category will have the highest CAGR, of 2.2%. This accelerated expansion is driven by the increasing demand for quantitative results, digital connectivity, and automated result interpretation. Digital and mobile readers, in particular, are experiencing exceptional growth as healthcare systems transition toward connected diagnostic ecosystems. These devices enable real-time data transmission, quality control monitoring, and integration with electronic health records, addressing the growing need for comprehensive disease surveillance and population health management. The convergence of reader technology with artificial intelligence and machine learning algorithms further enhances diagnostic accuracy while reducing user-dependent variability in result interpretation.
The product types analyzed in this report are:
The clinical testing category held the largest market share, of 75%, in 2024, due to its significance in the detection and identification of various disorders. Together with the surge in cases of infectious disorders and other medical diseases, the need for these assays is expected to rise. For instance, according to the World Health Organization’s Global Tuberculosis Report 2024, 1.25 million people died from TB in 2023, including 161,000 people with HIV. As a result, the increasing burden of tuberculosis is expected to propel the need for quick and affordable diagnostics, particularly in developing countries, which will drive the market.
Moreover, the rising demand for clinical testing is leading to new approvals of self-test kits, including TRUSTline HIV-Ab/Ag 4th Gen Rapid Test, Atomo HIV Self-Test, and Dr Trust HIV Sure, among others. This helps patients with assurance, early diagnosis, ease of use, and better convenience, which, in turn, drives the market in this category.
Within clinical testing, infectious disease testing represents the largest sub-category, fueled by the continuing need for rapid diagnosis of conditions, including COVID-19, influenza, HIV, malaria, and sexually transmitted infections. The cardiac marker testing sub-segment demonstrates robust growth potential, particularly for troponin I detection in emergency departments where rapid diagnosis of acute myocardial infarction is critical for patient outcomes.
The veterinary diagnostics category will have the highest CAGR, of 2.3%. This reflects increasing pet ownership globally, rising livestock disease surveillance requirements, and expanding regulatory mandates for animal health monitoring.
The applications analyzed in this report are:
The sandwich category held the largest market share, of 65%, in 2024. This is primarily ascribed to the enhanced sensitivity and specificity of these assays for larger analytes that have two epitopes or binding sites. The most-common kind of commercially paper-based biosensors is the sandwich lateral flow assay, which offers an affordable, accurate, quick, and single-step assay. For instance, the sandwich-based assay can provide results in just 20 minutes and can be utilized in low-resource healthcare facilities without needing the help of trained medical professionals.
These assays demonstrate exceptional performance in measuring critical biomarkers, including cardiac troponin I, infectious disease antigens, and pregnancy hormones. The widespread adoption of sandwich assays across diverse applications—from home pregnancy tests to professional cardiac marker detection—underscores their versatility and reliability in various testing environments.
The multiplex detection category will have the highest CAGR, of 2.4%. This remarkable growth trajectory reflects the increasing demand for comprehensive diagnostic panels that can simultaneously detect multiple pathogens or biomarkers from a single sample. Multiplex testing enhances efficiency by reducing sample volume requirements, decreasing time-to-result, and lowering per-analyte costs. This makes it particularly attractive for respiratory pathogen panels, sexually transmitted infection screening, and comprehensive cardiac risk assessment. Competitive assays, while maintaining a smaller market share, continue to serve critical niches in drug-of-abuse testing and small molecule detection where their unique detection mechanism provides optimal performance.
The techniques analyzed in this report are:
The blood category held the largest market share, of 45%, in 2024. This is due to the use of blood samples for performing lateral flow assays, and the lateral flow tests can detect various infectious diseases, including HIV, malaria, and syphilis, among others. Moreover, the growing knowledge of rapid solution providers, the easiness of detecting disease antigens from blood samples, and the increasing awareness regarding the rapid testing solutions and uncomplicated identification of disease antibodies from blood samples are driving the market growth in this category.
The saliva category will have the highest CAGR, of 2.4%. This is attributed to the non-invasive nature of saliva collection, making it particularly suitable for pediatric testing, frequent monitoring applications, and home-based diagnostics. The COVID-19 pandemic highlighted the effectiveness of saliva-based testing for infectious disease detection, catalyzing broader acceptance and development of saliva-compatible lateral flow assays. Urine samples maintain steady growth, particularly for pregnancy testing, drug-of-abuse screening, and certain infectious disease applications, where they offer convenience and non-invasive collection advantages.
The sample types analyzed in this report are:
The hospitals & clinics category held the largest market share, of 50%, in 2024, due to the surging adoption of point-of-care testing, rising patient focus toward early diagnosis, and technological advancements in diagnostic technologies. Additionally, the rise in the application scope of lateral flow assays in hospitals and clinics is propelling the growth of the market in this category. Lateral flow diagnostics are extensively used in these facilities, as they give rapid and accurate results for cardiac markers, infectious conditions, cholesterol testing/lipid profiling, pregnancy & fertility testing, and drug abuse testing.
Furthermore, in hospitals, these types of assays provide quantitative and qualitative detection of certain antigens and antibodies. Further, during the COVID-19 pandemic, lateral flow immunoassays were extensively utilized by hospitals and clinics to identify the infection at a large scale. Also, the need for advanced diagnostic solutions in clinical setups will support the penetration of the products over the upcoming years.
The homecare settings category will have the highest CAGR, of 2.5%, driven by the increasing emphasis on patient-centric care, rising healthcare costs prompting shifts to home-based monitoring, and technological advances enabling consumer-friendly test designs. The COVID-19 pandemic accelerated consumer acceptance of home testing, establishing new behavioral patterns that extend beyond infectious disease to encompass fertility monitoring, chronic disease management, and wellness screening. Diagnostic laboratories and pharmaceutical companies maintain substantial market shares, utilizing lateral flow assays for high-volume screening programs and quality control applications, respectively.
The end users analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America held the largest market share, of 40%, in 2024. This is due to the increased incidences of COVID-19, Lyme disease, and tuberculosis, and a rise in mortality rates related to HIV and AIDS in the region. This leadership position is underpinned by several key factors, including sophisticated healthcare infrastructure, substantial per capita healthcare expenditure, and rapid adoption of innovative diagnostic technologies. The region's market strength is particularly evident in the widespread implementation of point-of-care testing across diverse healthcare settings, from major hospital systems to retail clinics and pharmacy chains. Furthermore, the integration of lateral flow assays into telehealth platforms and direct-to-consumer healthcare models positions North America at the forefront of diagnostic democratization trends.
The U.S. accounts for the larger revenue share in the North American market. This is due to the rising pool of patients suffering from illnesses and high affordability with growing disposable income. Also, the outbreak of COVID-19 hit the country very hard and compelled the government to conduct mass screening programs. In addition, the reporting of rapidly spreading conditions, including urinary tract infections and meningitis, requires immediate diagnosis, which is further busting the demand for fast diagnostic test procedures. The presence of major diagnostic manufacturers, including Abbott Laboratories, QuidelOrtho Corporation, and multiple innovative startups, creates a dynamic competitive environment that drives continuous product advancement.
Asia-Pacific will have the highest CAGR, of 2.7%, driven by the confluence of rapidly expanding healthcare infrastructure, rising disease burden, and increasing healthcare accessibility initiatives. The rapid aging in Japan, China, and South Korea is fueling the demand for chronic disease monitoring and geriatric healthcare solutions.
Southeast Asian markets, including Indonesia, Thailand, and Vietnam, demonstrate robust growth potential driven by expanding universal healthcare coverage and increasing focus on diagnostic accessibility. Moreover, India's market expansion is fueled by its large population base, rising middle class with increasing healthcare spending capacity, and growing burden of both infectious and non-communicable diseases.
China emerges as the regional growth engine, combining massive population scale with rapidly modernizing healthcare systems and increasing government investment in diagnostic capabilities. The country's focus on primary healthcare strengthening and disease prevention programs creates substantial opportunities for lateral flow assay deployment across rural and urban settings. Moreover, China has faced several outbreaks of infectious diseases in recent years, including SARS and avian influenza, highlighting the critical importance of rapid diagnostic capabilities for outbreak response and disease surveillance.
The geographical breakdown of the market is as follows:
The market is consolidated with a few key players dominating due to their technical expertise, regulatory capabilities, and established distribution networks. Moreover, the growing demand for rapid and reliable diagnostic solutions has made the lateral flow assays market increasingly competitive. The global lateral flow assays market exhibits a consolidated structure, with the top 10 key players collectively controlling the total market share in 2024. This market concentration reflects the technical expertise, regulatory capabilities, and distribution networks required for the successful commercialization of diagnostic products. Moreover, market leaders maintain positions through innovation, strategic acquisitions, and digital integration, while opportunities exist in specialized segments like veterinary diagnostics and food safety, despite regulatory barriers.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages